Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Neutralizing antibodies target the receptor binding domain of the spike (S) protein, a focus of successful vaccine efforts. Concerns have arisen that S-specific vaccine immunity may fail to neutralize emerging variants. We show that vaccination with HAd5 expressing the nucleocapsid (N) protein can establish protective immunity, defined by reduced weight loss and viral load, in both Syrian hamsters and k18-hACE2 mice. Challenge of vaccinated mice was associated with rapid N-specific T cell recall responses in the respiratory mucosa. This study supports the rationale for including additional viral antigens, even if they are not a target of neutralizing antibodies, to broaden epitope coverage and immune effector mechanisms.
Competing Interest Statement
The authors have declared no competing interest.
Subject Area
- Biochemistry (11760)
- Bioengineering (8760)
- Bioinformatics (29211)
- Biophysics (14986)
- Cancer Biology (12104)
- Cell Biology (17417)
- Clinical Trials (138)
- Developmental Biology (9429)
- Ecology (14189)
- Epidemiology (2067)
- Evolutionary Biology (18316)
- Genetics (12246)
- Genomics (16807)
- Immunology (11875)
- Microbiology (28106)
- Molecular Biology (11607)
- Neuroscience (61019)
- Paleontology (452)
- Pathology (1872)
- Pharmacology and Toxicology (3238)
- Physiology (4964)
- Plant Biology (10429)
- Synthetic Biology (2888)
- Systems Biology (7341)
- Zoology (1651)